Methods	6 week randomised double blind study
Participants	Diagnosis: DSM-III major depressive disorder Setting: In- and outpatients
Interventions	1. Mirtazapine: 15-45 mg/day, N = 56 2. Amitriptyline: 30-90 mg/day, N = 59 Flexible dosing scheduling
Outcomes	The measure used for response and remission in the review: 21-item HAM-D Other measures: MADRS, CGI-Improvement, CGI-Severity, Brief Cognitive Rating Scale
Notes
Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: “randomised” Comment: No further information provided.
Allocation concealment (selection bias)	Unclear risk	Comment: The method of allocation is not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Quote: “double-blind” Comment: No further information provided.
Incomplete outcome data (attrition bias) All outcomes	High risk	More than 20% of the allocated participants to the mirtazapine arm dropped out during the study
Selective reporting (reporting bias)	High risk	Neither the response or remission outcomes at the end of acute-phase treatment are provided. They needed to be imputed in the analysis
Free of Sponsorship bias?	High risk	The funding source is the pharmaceutical company of mirtazapine